The search for the ideal thrombolytic agent

Area of Science:

• Biochemistry
• Pharmacology
• Thrombosis Research

Background:

• Streptokinase and urokinase are established thrombolytic agents.
• Existing thrombolytic therapies have limitations, including antigenicity and short half-lives.
• Improvements are sought to enhance efficacy and patient outcomes.

Purpose of the Study:

• To review strategies for improving streptokinase and urokinase.
• To explore methods for increasing fibrin specificity and prolonging half-life of thrombolytic agents.
• To discuss the potential of novel mutants and hybrids.

Main Methods:

• Fragmentation of streptokinase to reduce antigenicity.
• Coupling streptokinase with human plasminogen or polyethylene glycols.
• Immobilization of streptokinase and urokinase with water-soluble carriers.
• Antibody-mediated targeting of urokinase to fibrin.
• Development of mutants and hybrids of tissue-type plasminogen activator and single chain urokinase-type plasminogen activator.

Main Results:

• Plasmin B chain-streptokinase complex demonstrated increased potency.
• Immobilization strategies prolonged the half-life of thrombolytic agents.
• Fibrin-specific antibody coupling enhanced urokinase efficacy in vitro.
• Tissue-type plasminogen activator and single chain urokinase-type plasminogen activator offer relative fibrin specificity.

Conclusions:

• Various modification strategies can improve thrombolytic agents.
• Enhanced fibrin specificity and prolonged half-life are key goals for improved thrombolysis.
• Engineered molecules like mutants and hybrids hold promise for future therapeutic potential.